![](https://endpts.com/wp-content/uploads/2022/07/Sammy-Farah-Turnstone-Biologics-tile1.jpg)
Sammy Farah, Turnstone Biologics CEO
Takeda axes clinical-stage program in $1B+ Turnstone Biologics collaboration
Takeda has ended its work with Turnstone Biologics on a solid tumor asset that was in a Phase I/IIa study, upending a 2019 deal that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.